Loading the session
Loading the session
Loading instrument
$8.30
−4.38%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:38 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −19.3% (SPY −1.6%). 3 months: −17.6% (SPY −0.4%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: HELP, SPY · as of 4 Nov 2026
2 Nov 2026 volume of 3.9M shares was 2.7× the average of the 30 sessions before it (1.5M), as the price fell 16.9%. SPY traded 1.2× its own average that session.
Daily volume against a 30-session baseline · as of 2 Nov 2026
The 4 Nov 2026 close of $8.68 was 25.8% below its 50-day average ($11.70) and 12.3% above its 200-day average ($7.73).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
3.0M shares were sold short at the 15 Oct 2026 settlement, 3.8% of the 79.8M shares outstanding; covering them would take 1.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
June 25, 2026
+18.27%April 22, 2026
+17.04%March 5, 2026
−33.88%